Growing prevalence of diabetes (type I and type II) coupled with government initiatives to develop insulin in markets such as Brazil by providing medical and financial aid to the population in the form of subsidies and the entrance of multinational companies such as Novo Nordisk, Sanofi Aventis, etc is expected to drive regional insulin market. Affordability of medicines is perceived to be a key challenge for market development, as a significant part of the population may not be able to afford the product.
In 2013, Type II applications lead the regional market, with revenue of USD 1,183.7 million and are expected to grow at a CAGR of 15.8 % from 2014 to 2020. Type I applications are expected to have faster growth, at an estimated CAGR of 20.3 % from 2014 to 2020.
For Complete Report, Visit @ http://www.radiantinsights.com/research/latin-america-brazil-argentina-chile-mexico-colombia-venezuela-insulin-market-rapid-acting-short-acting-pre-mixed-long-acting-type-i-amp-ii-diabetes-analogs-recombinant-analysis-and-segment-forecasts-to-2020
Further key findings from the study suggest:
Long acting products dominated insulin demand in Latin America, with estimated revenue of USD 548.6 million in 2013. Other leading products include rapid acting and premixed analogs, with the latter expected to grow at a CAGR of 14.3 % from 2014 to 2020.
In 2013, Analog was a dominant insulin source and is expected to grow at a CAGR of 17.7 % from 2014 to 2020.
R&D initiatives, changing lifestyle affecting health of people specially children and growing rate of old aged (above 40) population are also expected to have a positive influence on market demand.
In 2013, Brazil was the largest regional insulin market in terms of revenue, accounting for 38.0% share of Latin American demand, followed by Mexico and Argentina. Brazil insulin demand is estimated to grow at a fastest CAGR of 18.2 % from 2014 to 2020.
Some of the key manufacturers in Latin American insulin market include Sanofi Aventis, Novo Nordisk, Nanjing Xinbai Pharmaceutical Co. Ltd, Takeda Pharmaceuticals, Eli Lilly and Company.
For other reports of this category, click here: http://www.radiantinsights.com/catalog/pharmaceutical
For the purpose of this study, Grand View Research has segmented the Asia Pacific Insulin market on the basis of product, application, source and region:
Insulin Product Outlook
Rapid acting
Long acting
Premixed
Premixed analog
Short acting
Intermediate acting
Insulin Application Outlook
Type II and Other Diabetes
Type I Diabetes
Insulin Source Outlook
Human Recombinant
Analogs
Insulin Regional Outlook
Brazil
Argentina
Chile
Mexico
Colombia
Venezuela
Peru
Rest of Latin America
About Radiant Insights
Radiant Insights is a platform for companies looking
to meet their market research and business intelligence requirements. It assist
and facilitate organizations and individuals procure market research reports,
helping them in the decision making process. The Organization has a
comprehensive collection of reports, covering over 40 key industries and a host
of micro markets. In addition to over extensive database of reports,
experienced research coordinators also offer a host of ancillary services such
as, research partnerships/ tie-ups and customized research solutions.
Media
Contact:
Company Name: Radiant Insights, Inc
Contact Person: Michelle Thoras
Email: sales@radiantinsights.com
Phone: (415) 349-0054
Address: 28 2nd Street, Suite 3036
City: San Francisco
State: California
Country: United States
No comments:
Post a Comment